DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Novo Nordisk obtains licence for sickle cell disease program
Novo Nordisk inked a global licence deal with biotech company EpiDestiny for sickle cell disease (“SCD”) program EPI01.
Per the deal, EpiDestiny will receive more than $400 million in upfront, development and sales milestone payments and will also get royalties on net sales. EpiDestiny retains all rights to continue development of EPI01 in oncology. EpiDestiny and Novo Nordisk will jointly develop EPI01 for SCD and beta-thalassaemia.
EPI01 is a novel, orally available, disease-modifying therapy to increase foetal haemoglobin (HbF) and interrupt SCD pathophysiology. EpiDestiny recently completed a phase I study with EPI01 in SCD patients demonstrating increased HbF expression and safety after eight weeks of administration in a small patient cohort.


Related Content
-
education & researchA Clinically Meaningful Fetal Hemoglobin Threshold for Children With Sickle Cell Anemia During Hydroxyurea TherapyHydroxyurea has proven clinical benefits...
-
news & eventsSCDAA News Advisory: SCDAA Statement on Exa-cel Gene TherapyOn October 31, 2023, the Food and Drug A...
-
news & eventsFDA grants CRISPR gene therapy fast track designation for sickle cell diseaseThe FDA granted fast track designation t...
-
news & eventsBluebird bio acquires Durham, NC, manufacturing site for lentiviral vector productionbluebird bio said today it has acquired ...
-
education & researchHaematopoietic stem cell transplantation for sickle cell disease – current practice and new approachesSickle cell disease is an inherited diso...
-
news & eventsInvestigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell TrialSancilio Pharmaceuticals says its invest...
-
news & eventsPartnership to Ensure Supply of LentiGlobin, Potential Gene TherapyBluebird Bio extended a partnership with...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.